Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Global Platform
Monday, March 09, 2026
Royalty Pharma plc, a leading buyer of biopharmaceutical royalties, has announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Based in Hong Kong, Sun will spearhead the company's royalty business across Asia, capitalizing on the region's rapid growth in biotechnology innovation.
Sun joins from Morgan Stanley, where he served as Head of Asia Pacific Healthcare Investment Banking. His extensive experience positions him ideally to navigate the evolving funding landscape for Asian biotech firms. In 2025, out-licensing of Chinese medicines alone generated over $130 billion in transaction value, a sharp rise from $14 billion in 2021, reflecting multinational pharma's growing recognition of Asian innovation[1].
This surge underscores a burgeoning opportunity for royalty-based funding, a model Royalty Pharma pioneered in the West over two decades ago through partnerships with universities, research institutions, and biopharma companies. The firm aims to replicate this success in Greater Asia by offering flexible, non-dilutive capital to innovators amid increasingly diverse deal structures, modalities, and therapeutic areas.
"We are excited to welcome Ken, who has a deep and strategic understanding of the funding needs created by the incredible innovation occurring across Asia," stated Pablo Legorreta, CEO and Chairman of Royalty Pharma. He emphasized the importance of on-the-ground expertise and local relationships in unlocking Asia's long-term potential for royalty financing and creative structures[1].
Sun expressed enthusiasm for the role: "Royalty creation in Asia has grown rapidly and represents a potentially important new source of flexible, non-dilutive capital at significant scale to innovative biotech companies." He highlighted Royalty Pharma's leadership in the royalty market as pivotal for advancing regional biopharma innovation[1].
Founded in 1996, Royalty Pharma funds innovation across the biopharmaceutical spectrum, from academic institutions to global pharma giants. Its portfolio includes royalties on over 35 commercial products, such as Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Biogen’s Tysabri and Spinraza, Roche’s Evrysdi, and others, plus 20 development-stage candidates[1].
This strategic hire aligns with broader trends in Asia's biopharma sector, where deal-making and R&D investments are accelerating. Royalty Pharma's expansion into Asia not only strengthens its global platform but also supports biotech firms seeking alternatives to traditional venture capital, fostering sustainable growth in drug development and commercialization.
The appointment comes at a time when Asian markets are seeing heightened M&A and licensing activity. For instance, Chinese biotechs are increasingly partnering with Western firms, driving record transaction volumes. Royalty Pharma's focus on royalties provides a unique value proposition, enabling originators to retain equity while monetizing future revenues[1].
Industry observers view this move as a signal of Royalty Pharma's confidence in Asia's trajectory. With Sun's leadership, the company is poised to build a robust royalty ecosystem, mirroring its Western success. This initiative will likely catalyze further investment in Asian R&D, clinical trials, and manufacturing, enhancing the region's role in global life sciences.
Challenges remain, including regulatory harmonization and IP protection, but Royalty Pharma's track record suggests effective navigation. Sun's banking background will aid in forging partnerships with key stakeholders, from startups to multinationals, solidifying Asia's position in biopharma financing[1].
Overall, this development exemplifies executive-level strategies in the pharma industry, emphasizing talent acquisition to tap into high-growth markets. It bodes well for B2B collaborations, potentially unlocking billions in royalty deals and propelling Asian innovation onto the world stage.
